Actively Recruiting

Phase 1
Age: 12Years - 45Years
All Genders
NCT03918408

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking

Led by Pacific Clear Vision Institute · Updated on 2024-11-12

300

Participants Needed

1

Research Sites

587 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To determine whether the Peschke PXL-330 system is safe and effective in the treatment of corneal thinning conditions.

CONDITIONS

Official Title

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking

Who Can Participate

Age: 12Years - 45Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 12 years of age or older
  • Evidence of progressive keratoconus as shown by worsening astigmatism, asymmetry, or vision over the last 3 or more months
  • Presence of central or inferior corneal steepening
  • Corneal topography consistent with keratoconus
  • One or more keratoconus signs such as Fleischer ring, Vogt's striae, decentered corneal apex, Munson's sign, Rizzutti's sign, apical corneal scarring, scissoring retinoscopic reflex, or crab-claw appearance on topography
  • Steepest keratometry (Kmax) value of 47.20 diopters or higher
  • I-S keratometry difference greater than 1.5 diopters on topography maps
  • Posterior corneal elevation over 16 microns
  • Thinnest corneal point less than 485 microns
  • High genetic keratoconus risk score (67 or higher) on AvaGen testing
  • Signed informed consent
  • Willingness and ability to attend follow-up visits
  • Contact lens wearers must discontinue lenses as specified before screening
Not Eligible

You will not qualify if you...

  • Eyes classified as normal or atypical normal on severity grading
  • Corneal thickness below 330 microns at the thinnest point
  • Previous or active corneal diseases aside from refractive error, such as herpes keratitis or recurrent erosion syndrome
  • Significant corneal scarring in the treatment zone not related to keratoconus
  • Pregnancy or lactation during the study
  • Known allergy to study medications
  • Nystagmus or inability to maintain steady gaze during treatment or tests
  • Active medical implants like pacemakers
  • Aphakic or pseudophakic eyes

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Pacific Clear Vision Institute

Eugene, Oregon, United States, 97401

Actively Recruiting

Loading map...

Research Team

B

BALAMURALI AMBATI, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here